Sells it 4%, $2.6B a year“AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies.”
Latest 10-KFY2025PositiveImpairment / charge ·
Skyrizi and Rinvoq more than offset Humira’s biosimilar losses; acquisition-related charges and a tax-rate reversal kept net earnings flat.
Revenue$61.2BYoY +8.6%
Net income$4.2BYoY −1.2%
Latest 10-QQ3 FY2026Positive ·
Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.
Revenue$17.4BYoY +10.3%
Net income$4.2Bvs $186.0M year ago
Latest 8-KLeadership change ·
Jennifer L. Davis resigned from AbbVie’s board following her appointment as Align Technology CEO.
Sells it“We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases.”
Sells it 100%, $36.8B a year“Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
In development“We are a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.”
Sells it“We are a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using our proprietary bacteriophage-based technology.”
Convertible-loan fair-value losses drove the net loss; Innoviva credit maturities were extended amid a going-concern warning.
Latest 8-KDebt financingGovernance change ·
Innoviva subsidiary extends credit maturities and warrant expirations; FDA approval of a product candidate now triggers early termination of the voting agreement.
Sells it“Aspen Neuroscience, Inc. is a leading, clinical-stage regenerative medicine biotechnology company focused on developing autologous iPSC-derived therapies to address neurodegenerative diseases with high unmet medical need.”
Sells it“We are a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.”
In development“We are a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation (“I&I”) and fundamentally improve patient quality of life.”
Sells it“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”
Sells it 100%, $48.2B a year“We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases.”
Latest 10-KFY2025MixedImpairment / charge ·
Reblozyl, Breyanzi and Camzyos gains offset Revlimid erosion; lower acquisition charges drove the GAAP earnings rebound.
Revenue$48.2BYoY −0.2%
Net income$7.1Bvs −$8.9B year ago
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.
Sells it“We are a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases.”
In development“Capricor is a clinical-stage biotechnology company developing cell- and exosome-based therapies, including Deramiocel for Duchenne muscular dystrophy (DMD).”
Latest 10-QQ3 FY2026NegativeRestructuring ·
Deramiocel’s FDA bid narrows to upper-limb impairment after an adverse cardiac efficacy vote; a Nippon Shinyaku dispute complicates launch plans.
Sells it“We are a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful, durable benefits for patients in need.”
Sells it“We are a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer.”
Sells it 99%, $408.0M a year“Innoviva, Inc. (“Innoviva”, the “Company”, the “Registrant” or “we” and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic healthcare assets.”
Latest 10-KFY2025Positive ·
GIAPREZA and XACDURO lifted product sales, but at-cost Zai Lab supply limited margins; Armata investment gains drove GAAP earnings.
Revenue$411.3MYoY +14.7%
Net income$271.2Mvs $23.4M year ago
Latest 10-QQ3 FY2026Positive ·
XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings
Revenue$106.1MYoY −1.6%
Net income−$73.9Mvs $89.9M year ago
Latest 8-KEarningsGuidance reaffirmed ·
Lower royalties and ex-U.S. sales timing weighed on revenue; $139.5M in investment markdowns, mainly Armata, drove the net loss.
Latest 8-KLeadership change ·
Derek Small and Mark DiPaolo resign from the board to grow Syndeio BioSciences; Josephine Linden joins.
Latest 8-KShareholder voteExecutive pay ·
Stockholders approved the 2026 Equity Incentive Plan and elected five directors to one-year terms.
Sells it 64%, $60.4B a year“Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.”
Latest 10-KFY2025 ·
DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.
Sells it“We are a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction.”
In development“We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases.”
Sells it 74%, $48.0B a year“Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders.”
Latest 10-KFY2025Restructuring ·
China Gardasil inventory overhang blunted Keytruda and Winrevair growth; launches and acquisitions seek replacement revenue.
Revenue$65.0BYoY +1.3%
Net income$18.3BYoY +6.6%
Latest 10-QQ3 FY2026Impairment / charge ·
Keytruda Qlex offsets IV declines; purchase timing lifts sales as pipeline acquisitions weigh on earnings.
Revenue$18.1BYoY +4.7%
Net income$5.1BYoY −12.4%
Latest 8-KLeadership change ·
Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.
In development“We are a clinical-stage biopharmaceutical company developing innovative oxygen therapeutic solutions for the treatment of diseases where hypoxia, or lack of oxygen, plays a critical role.”
Sells it 94%, $4.8B a quarter“Global product sales provide additional context but are not all recorded as Regeneron revenue: Sanofi records Dupixent sales and Regeneron receives a profit share; Regeneron records U.S. EYLEA sales while Bayer records ex-U.S. sales and shares profits.”
Latest 10-QQ3 FY2026Positive ·
Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.
Revenue$5.1BYoY +36.3%
Net income$1.9BYoY +33.5%
Latest 8-KPositiveEarningsGuidance raised ·
Higher Dupixent profit share and the end of Sanofi Development Balance deductions accelerated revenue growth to 36% Y/Y.
Expanded Sanofi pact covers four long-acting antibodies with $1.0B upfront and up to $7.0B in milestones, and settles information-access lawsuit.
Latest 8-KExecutive pay ·
10-year CEO and chief scientific officer equity awards replace annual grants through 2036, tying payouts to new-product revenue and pipeline milestones.
In development“We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly owned oral inhibitors of NLRP3.”
Sells it“We are a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.”
In development“In addition, we use our computational platform to discover novel molecules for our pipeline of proprietary drug discovery programs, which we are advancing through preclinical and clinical development.”
Latest 10-KFY2025MixedRestructuring ·
Novartis collaboration work and hosted-software sales drove growth, but higher delivery costs squeezed gross margin.
In development“We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems.”
In development“We are a clinical-stage life science and drug development company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis.”
Sells it“We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis.”